Nureeto-MR 8 Tablet is a combination medication containing Etoricoxib 60 mg and Thiocolchicoside 8 mg, formulated for the management of musculoskeletal pain and inflammatory conditions. Etoricoxib, a selective COX-2 inhibitor, provides effective analgesic and anti-inflammatory effects by selectively inhibiting the cyclooxygenase-2 enzyme, thereby reducing prostaglandin synthesis responsible for pain and inflammation. Thiocolchicoside, a muscle relaxant with anti-inflammatory properties, acts by modulating glycine and GABA receptors in the central nervous system, leading to relief from muscle spasms and associated discomfort. This combination is particularly beneficial in conditions such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and acute musculoskeletal injuries where both pain and muscle spasm coexist. Nureeto-MR 8 Tablet offers improved patient compliance by addressing multiple symptoms with a single dosage form. It is generally well tolerated; however, caution is advised in patients with cardiovascular disease, gastrointestinal disorders, or hepatic impairment. The medication should be used under medical supervision, adhering to prescribed dosages to minimize adverse effects. Regular monitoring is recommended during prolonged therapy. Nureeto-MR 8 Tablet provides an effective therapeutic option for comprehensive management of inflammatory and musculoskeletal conditions requiring both analgesic and muscle relaxant actions.